NEW PSYCHOACTIVE SUBSTANCES: THE END OF DRUG EVOLUTION OR THE FIRST STEP.
Abstract
In the last 10-15 years the world witnesses the polymorphism of the usual pattern of drug addiction, characterized by an increase in the supply of new psychoactive substances (NPS), which leads not only to the change in clinical drug addiction, but also to the emergence of new social problems. Regulatory authorities, such as UNIDOC note that each year several hundred NPS are being synthesized, in order to "replace" those substances, the circulation of which is banned at the legislative level. This review is performed to update the historical records of new generations of NPS that have appeared on the illicit market, "replacing" those substances that are prohibited at the legislative level. This paper describes psychotropic properties, metabolism, methods of consumption, clinical features, associated with use of NPS.
About the Authors
A. R. Asadullin
ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
A. V. Antsyborov
Медицинский центр «Ковчег», Ростовская область
Russian Federation
Russian Federation
References
1. Асадуллин, А.Р. Катиноны. Новая реальность / А.Р. Асадуллин, Э.А. Ахметова, А.Ю. Ненастьева // Наркология. - 2017. - № 1. - С. 87-92
2. Ахметова, Э.А. Дисгармоничная семья как фактор формирования зависимости к новым синтетическим «дизайнерским» наркотикам / Э.А. Ахметова // Медицинский вестник Башкортостана. - 2017. - № 1. - С. 15-20
3. Кибитов, А.О. Клиническая генетика наркологических заболеваний: роль генов системы дофамина / А.О. Кибитов // Вопросы наркологии. - 2013. - №. 6. - С. 60-80
4. Мрыхин, В.В. Психиатрические аспекты употребления дизайнерских наркотиков и новых психоактивных веществ / В.В. Мрыхин, А.В. Анцыборов // Интерактивная наука. - 2017. - № 12. - С. 64-74
5. Особенности распространенности и потребления синтетических дизайнерских наркотических средств на территории Республики Башкортостан / В.Л. Юлдашев [и др.] // Сибирский вестник психиатрии и наркологии - 2016. - № 3. - С. 69-75
6. Adamowicz, P. Simple and rapid screening procedure for 143 new psychoactive substances by liquid chromatography-tandem mass spectrometry / P. Adamowicz, B. Tokarczyk // Drug Test. Anal. - 2015. doi: 10.1002/dta.1815
7. Raising awareness of new psychoactive substances: chemical analysis and in vitro toxicity screening of ‘legal high’ packages containing synthetic cathinones / A.M. Araújo [et al.] //Arch. Toxicol. - 2015. - Vol. 89. - P. 757-771
8. Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22 / G. Behonick [et al.] //J. Anal. Toxicol. - 2014. - Vol. 38. - P. 559-562
9. Impact of a synthetic cannabinoid (CP-47,497-C8) on protein expression in human cells: evidence for induction of inflammation and DNA damage / A. Bileck [et al.] // Biomed. Life Sci. - 2015. - Vol. 969. - P. 272-284
10. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications / M.S. Castaneto [et al.] // Drug Alcohol Depend. - 2014. - Vol. 144. - P. 12-41
11. Corazza, O. From "Special K" to "Special M": the evolution of the recreational use of ketamine and methoxetamine / O. Corazza, S. Assi, F.Schifano // CNS Neurosci. Ther. - 2013. - Vol. 19. - P. 454-460
12. EMCDDA, 2014a. European Drug Report 2014a. Trends and developments. URL: http://www.emcdda.europa.eu/ attachements.cfm/att_228272_EN_ TDAT14001ENN.pdf. Accessed on October 22, 2016
13. Gatch, M.B. Δ9-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids found on the gray market / M.B. Gatch, M.J. Forster // Behav. Pharmacol. - 2015. - Vol. 26. - P. 460-468
14. Pharmacology of novel synthetic stimulants structurally related to the "bath salts" constituent 3,4-methylenedioxypyrovalerone (MDPV) / J.A. Marusich [et al.] // Neuropharmacology. - 2014. - Vol. 87. - P. 206-213
15. Neonatal withdrawal syndrome after chronic maternal consumption of 4 -methylethcathinone / S. Pichini [et al.]// Forensic Sci. Int. - 2014. - Vol. 245. - P. 33-35
Review
For citations:
Asadullin A.R., Antsyborov A.V. NEW PSYCHOACTIVE SUBSTANCES: THE END OF DRUG EVOLUTION OR THE FIRST STEP. Bashkortostan Medical Journal. 2017;12(4):98-103. (In Russ.)
Views:
161
Email this article 
